Healthcare Executive Search Company, Berke Executive Search, Announces Chronic Obstructive Pulmonary Disease Market to Face Challenges in 2016 and Beyond
At the end of 2015, experts assessed the global market for Chronic Obstructive Pulmonary Disease (COPD) treatments. Their analysis showed strong growth in the sector, with total research funding set to increase on a compounded annual rate of 2.9 percent, reaching $11.2 billion by 2021. Interest in the disease sparked a steady increase in executive searches for candidates with experience in the field.
Philadelphia, PA, June 02, 2016 --(PR.com)-- The rise in COPD funding comes at a time when the leading treatments for the disease have come to the end of their original patents. For years, Spiriva (Pfizer), Advair (GSK), and Symbicort (AstraZeneca) controlled the vast majority of the COPD market, and few companies made serious inroads into new research.
As the patents on these key drugs expire, few replacements exist in the FDA approval pipeline. Bevespi Aeropshere from AstraZeneca, approved in April 2016, is an addition-in-class product that offers few new benefits for patients. Stiolto Respimat and Utibron Neohaler received approval at the end of 2015, but both drugs are designed for disease maintenance rather than prevention or cure.
The major players already in the market, in particular GlaxoSmithKline, are prepared to launch a new line of drugs in 2017 that will help them hold on to some of their existing market share; however, the market is ready for new insight.
The team at Berke Executive Search anticipates requests for healthcare executives focused on first-in-class products that will redefine the treatment of COPD. Research into treatments that slow or reverse the progress of the disease, and into long-term treatment options, could open the door for smaller companies and labs to make an impact.
Despite lower rates of smoking around the world, an aging population produces many potential COPD patients, and companies could seize enormous profits with a treatment breakthrough. Companies like Berke Executive Search are necessary to perform a thorough healthcare executive search that brings the right research talent and managers to the right company, in order to develop the next generation of COPD drugs.
About Berke
As a retained executive search firm, Berke Executive Search takes the lead in the hiring process for CXO and top-level researchers. Berke Executive Search focuses solely on the Bio Pharma and Life Science industries, giving the firm's search teams an in-depth knowledge of the industry.
For more information, please visit www.berkesearch.com or call 267-483-8951.
As the patents on these key drugs expire, few replacements exist in the FDA approval pipeline. Bevespi Aeropshere from AstraZeneca, approved in April 2016, is an addition-in-class product that offers few new benefits for patients. Stiolto Respimat and Utibron Neohaler received approval at the end of 2015, but both drugs are designed for disease maintenance rather than prevention or cure.
The major players already in the market, in particular GlaxoSmithKline, are prepared to launch a new line of drugs in 2017 that will help them hold on to some of their existing market share; however, the market is ready for new insight.
The team at Berke Executive Search anticipates requests for healthcare executives focused on first-in-class products that will redefine the treatment of COPD. Research into treatments that slow or reverse the progress of the disease, and into long-term treatment options, could open the door for smaller companies and labs to make an impact.
Despite lower rates of smoking around the world, an aging population produces many potential COPD patients, and companies could seize enormous profits with a treatment breakthrough. Companies like Berke Executive Search are necessary to perform a thorough healthcare executive search that brings the right research talent and managers to the right company, in order to develop the next generation of COPD drugs.
About Berke
As a retained executive search firm, Berke Executive Search takes the lead in the hiring process for CXO and top-level researchers. Berke Executive Search focuses solely on the Bio Pharma and Life Science industries, giving the firm's search teams an in-depth knowledge of the industry.
For more information, please visit www.berkesearch.com or call 267-483-8951.
Contact
Berke Executive Search
Carl Berke
267-483-8951
www.berkesearch.com
Carl Berke
267-483-8951
www.berkesearch.com
Contact
Categories